By Salma El-Sakka
The Department of Health and Human Services announced Wednesday it will temporarily permit compounding pharmacies to provide six peptides by prescription, including BPC-157, TB-500, epitalon, MOTS-c, KPV and semax. The substances have been promoted online for benefits ranging from tissue repair to longevity, though scientific evidence for such claims remains limited.
Policy details and safety measures
The policy does not grant FDA approval or establish clinical safety and effectiveness, HHS said. It requires patient-specific prescriptions, traceable ingredients, quality testing and safety reporting to hold compounders accountable and offer an alternative to unregulated sellers. An independent FDA advisory panel voted in July to recommend the six peptides for the 503A bulks list, which allows their use in individualized prescriptions.
Medical community concerns
Doctors warn that these unregulated products may not match advertised contents and could be contaminated or inaccurately dosed. No published clinical trials demonstrate effectiveness in humans for any condition. In 2023, the FDA classified 19 peptides as unsafe for compounding, a decision HHS Secretary Robert F. Kennedy Jr. previously called illegal.
